ArticleMolecular therapy. Advances2026
Chemistry-mediated synthetic virus-cell interaction as a generic approach to enhance gene delivery to mammalian cells.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Lentiviral vectors (LVs) that facilitate gene delivery to desired cell types have been widely used in routine laboratory research and therapeutic cell engineering. However, the lack of proper entry receptors on many cell types often results in poor gene delivery. Here, we leveraged biocompatible chemistries to establish a synthetic virus-cell interaction for enhancing virus entry. LVs are dual-pseudotyped with the G protein from vesicular stomatitis virus (VSV-G) and a chimeric envelope protein specifically recognizing a small molecule fluorescein (αFITC-Env). We created surrogate receptors for LV attachment by leveraging N-hydroxysuccinimide (NHS) chemistry to create a covalent bond between lysine on cell surface proteins and a small molecule fluorescein isothiocyanate (FITC) or by labeling cells with a FITC-conjugated antibody. The synthetic virus-cell interaction promotes robust virus docking and transgene delivery in a range of mammalian cell lines and primary T cells. We showed that this approach enabled efficient delivery of a CD19-targeted chimeric antigen receptor (CAR) into naive human T cells that are naturally refractory to conventional VSV-G LVs. These naive CD19-CAR T cells, upon activation, rapidly eradicated CD19
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.